# KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

> **NCT05906524** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Kanda Biotechnology Co., Ltd.** · enrollment: 85 (estimated)

## Conditions studied

- Advanced HCC
- Other Solid Tumors

## Interventions

- **DRUG:** KD6001
- **DRUG:** Tislelizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05906524
- **Lead sponsor:** Shanghai Kanda Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-15
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2024-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05906524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05906524, "KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05906524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*